BioMark Diagnostics Inc.

BioMark Diagnostics Inc.

BioMark Diagnostics Inc.

BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the detection and quantitation of metabolites. Our global enterprise team of proven scientists, engineers and medical professionals is hand-picked. The company’s goal is to commercialize our innovative technology. And we strive to increase the predictive accuracy in early stage cancer detection. We adhere to and follow the highest regulatory, clinical and scientific standards. Since 2007, our mission and team commitment remains the same. Develop and commercialize innovative technologies. Increase the prediction and accuracy of early stage diagnosis of cancers.

Company details

130 - 3851 Shell Road , Richmond , British Columbia V6X 2W2 Canada
View in map

Find locations served, office locations

Business Type:
Manufacturer
Industry Type:
Medical Equipment
Market Focus:
Globally (various continents)

Empowering People

It’s not only about physicians and medical institutions. Our goal is to empower people and nations. To provide universal access to effective cancer diagnostic tools.
 
At BioMark we speed up and make available effective cancer management solutions. We strive to improve patient outcomes.

Adherence To Rigorous Standards

Biomarkers play a critical role in all stages of disease. This is why rigorous evaluation is important. Analytical validation, clinical validation, and assessment of clinical utility. Each is important before the incorporation of routine clinical care. This is an important dimension of BioMark’s daily operational activity.

Dr. Greame F. Woodworth (MD) will be leading the initial Glioblastoma Multiforme resection. The goal is to correlate Glioblastoma Multiforme resection to existing anatomical imaging tests. Dr. Woodworth is a Professor at the University of Maryland, Department of Neurosurgery. He is also the Director of the Brain Tumor Treatement and Research Center. DR. Woodworth will serve as the University’s principle investigator for the study.
 
The co-PI is Dr. Chetan Bettegowda of Johns Hopkins. He serves as the Director Meningioma Center and Associate Professor of Neurosurgery.
 
Dr. Christian D. Rolfo (MD, PhD, MBA) will lead BioMark’s lung cancer panel. The panel validates the study and use in early lung cancer screening initiatives. The panel also handles measuring the response to treatments. Dr. Rolfo is a Professor, Department of Medicine. He is also the Director, Early Phase Clinical Trials Department of Medicine. And he is the Director, Thoracic Medical Oncology – Department of Medicine. Dr. Rolfo will serve as UMB’s principal investigator in connection with such study(ies).